Jiangsu Hansoh Pharmaceutical Group Co., Ltd.;Shanghai Hansoh Biomedical Co., Ltd.
发明人:
Peng GAO,Wenhua XIU,Shaobao WANG,Lei LIU,Rudi BAO
申请号：
US16302374
公开号：
US20190276451A1
申请日:
2017.05.16
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention relates to an FGFR4 inhibitor having a structure represented by formula (I), preparation method therefor, and applications thereof. A series of compounds represented by formula (I) in the present invention have very-strong inhibition effect on the activity of FGFR4 kinase, have very-high selectivity, can be widely used in the preparation of drugs for treating cancers, specially a liver cancer, a stomach cancer, a prostate cancer, a skin cancer, an ovarian cancer, a lung cancer, a breast cancer or a colon cancer, and can be developed into a new-generation FGFR4 inhibitor drug.
